How to Treat Today? Oral and Facial Cancer-Associated Venous Thromboembolism

The exact incidence of cancer-associated venous thromboembolism (CA-VTE) in patients with oral and facial cancer (OFC) is not exactly known, and this risk is empirically considered to be low. However, this suggestion may result in disease underdiagnosis, prolong the initiation of adequate therapy, a...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceuticals (Basel, Switzerland) Switzerland), 2023-07, Vol.16 (7), p.1011
Main Authors: Janíčková, Mária, Bolek, Tomáš, Stančiaková, Lucia, Nagy, Norbert, Mokáň, Marián, Samoš, Matej
Format: Article
Language:English
Subjects:
Anticoagulants
Blood clots
Blood platelets
Cancer therapies
cancer-associated venous thromboembolism
Care and treatment
Catheters
Clinical medicine
Clinical practice guidelines
Complications and side effects
Diagnosis
direct oral anticoagulants
Head and neck cancer
Hemorrhage
Leukocytes
Neutrophils
oral and facial cancer
Oral cancer
Pancreatic cancer
parenteral anticoagulation
Patients
Pulmonary embolisms
Review
Risk factors
Thromboembolism
Thrombosis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c499t-abd20921edbe55696a547427c900be5ecf7096037e7c44835e828fb71d4445103
container_end_page
container_issue 7
container_start_page 1011
container_title Pharmaceuticals (Basel, Switzerland)
container_volume 16
creator Janíčková, Mária
Bolek, Tomáš
Stančiaková, Lucia
Nagy, Norbert
Mokáň, Marián
Samoš, Matej
description The exact incidence of cancer-associated venous thromboembolism (CA-VTE) in patients with oral and facial cancer (OFC) is not exactly known, and this risk is empirically considered to be low. However, this suggestion may result in disease underdiagnosis, prolong the initiation of adequate therapy, and consecutively increase CA-VTE-related morbidity and mortality. In addition, there might be specific clinical problems in the treatment of CA-VTE in patients with oral and facial cancer, such as swallowing difficulties, that might limit the possibilities of oral anticoagulation. Finally, there are limited data regarding the optimal treatment of CA-VTE in patients with oral and facial cancer, and this includes data on novel therapeutic strategies, including the use of direct oral anticoagulants. This article reviews current data on the optimal treatment strategy for CA-VTE in patients with OFC.
doi_str_mv 10.3390/ph16071011
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_5d5ac398e8a44086b967aea82ecc4367</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A759189640</galeid><doaj_id>oai_doaj_org_article_5d5ac398e8a44086b967aea82ecc4367</doaj_id><sourcerecordid>A759189640</sourcerecordid><originalsourceid>FETCH-LOGICAL-c499t-abd20921edbe55696a547427c900be5ecf7096037e7c44835e828fb71d4445103</originalsourceid><addsrcrecordid>eNptUk1rGzEQXUpLk6a99AeUhV5KYFN9f5yCMU0TMOTi9iq00qwts7typXVK_n3lOE3iUoTQ6OnNG81jquojRheUavR1u8YCSYwwflWdYkZYowiTr1_EJ9W7nDcIcYkZfludUMkx1YSeVovr-LueYr1MYKd6Gb29v6xvk-1rO_r6yrpQwrkdHaRmlnMs9wl8_RPGuMv1cp3i0EYouw95eF-96Wyf4cPjeVb9uPq2nF83i9vvN_PZonFM66mxrSdIEwy-Bc6FFpYzyYh0GqGCgOsk0gJRCdIxpigHRVTXSuwZYxwjelbdHHR9tBuzTWGw6d5EG8wDENPK2DQF14PhnltHtQJlGUNKtFpIC1YRcI5RIYvW5UFru2sH8A7GqXR_JHr8Moa1WcU7U_6hOFekKHx5VEjx1w7yZIaQHfS9HaGYZIgqlbUQmhfq53-om7hLY_Fqz6JIcYTYM2tlSwdh7GIp7PaiZia5xkoLtjfh4j-ssjwMwcURulDwo4TzQ4JLMecE3VOTGJn9IJnnQSrkTy9teaL-nRz6BxCKv4Q</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2843085004</pqid></control><display><type>article</type><title>How to Treat Today? Oral and Facial Cancer-Associated Venous Thromboembolism</title><source>PubMed (Medline)</source><source>Publicly Available Content Database</source><creator>Janíčková, Mária ; Bolek, Tomáš ; Stančiaková, Lucia ; Nagy, Norbert ; Mokáň, Marián ; Samoš, Matej</creator><creatorcontrib>Janíčková, Mária ; Bolek, Tomáš ; Stančiaková, Lucia ; Nagy, Norbert ; Mokáň, Marián ; Samoš, Matej</creatorcontrib><description>The exact incidence of cancer-associated venous thromboembolism (CA-VTE) in patients with oral and facial cancer (OFC) is not exactly known, and this risk is empirically considered to be low. However, this suggestion may result in disease underdiagnosis, prolong the initiation of adequate therapy, and consecutively increase CA-VTE-related morbidity and mortality. In addition, there might be specific clinical problems in the treatment of CA-VTE in patients with oral and facial cancer, such as swallowing difficulties, that might limit the possibilities of oral anticoagulation. Finally, there are limited data regarding the optimal treatment of CA-VTE in patients with oral and facial cancer, and this includes data on novel therapeutic strategies, including the use of direct oral anticoagulants. This article reviews current data on the optimal treatment strategy for CA-VTE in patients with OFC.</description><identifier>ISSN: 1424-8247</identifier><identifier>EISSN: 1424-8247</identifier><identifier>DOI: 10.3390/ph16071011</identifier><identifier>PMID: 37513923</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Anticoagulants ; Blood clots ; Blood platelets ; Cancer therapies ; cancer-associated venous thromboembolism ; Care and treatment ; Catheters ; Clinical medicine ; Clinical practice guidelines ; Complications and side effects ; Diagnosis ; direct oral anticoagulants ; Head and neck cancer ; Hemorrhage ; Leukocytes ; Neutrophils ; oral and facial cancer ; Oral cancer ; Pancreatic cancer ; parenteral anticoagulation ; Patients ; Pulmonary embolisms ; Review ; Risk factors ; Thromboembolism ; Thrombosis</subject><ispartof>Pharmaceuticals (Basel, Switzerland), 2023-07, Vol.16 (7), p.1011</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c499t-abd20921edbe55696a547427c900be5ecf7096037e7c44835e828fb71d4445103</cites><orcidid>0000-0001-8086-1422 ; 0000-0002-5561-2560</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2843085004/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2843085004?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,74998</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37513923$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Janíčková, Mária</creatorcontrib><creatorcontrib>Bolek, Tomáš</creatorcontrib><creatorcontrib>Stančiaková, Lucia</creatorcontrib><creatorcontrib>Nagy, Norbert</creatorcontrib><creatorcontrib>Mokáň, Marián</creatorcontrib><creatorcontrib>Samoš, Matej</creatorcontrib><title>How to Treat Today? Oral and Facial Cancer-Associated Venous Thromboembolism</title><title>Pharmaceuticals (Basel, Switzerland)</title><addtitle>Pharmaceuticals (Basel)</addtitle><description>The exact incidence of cancer-associated venous thromboembolism (CA-VTE) in patients with oral and facial cancer (OFC) is not exactly known, and this risk is empirically considered to be low. However, this suggestion may result in disease underdiagnosis, prolong the initiation of adequate therapy, and consecutively increase CA-VTE-related morbidity and mortality. In addition, there might be specific clinical problems in the treatment of CA-VTE in patients with oral and facial cancer, such as swallowing difficulties, that might limit the possibilities of oral anticoagulation. Finally, there are limited data regarding the optimal treatment of CA-VTE in patients with oral and facial cancer, and this includes data on novel therapeutic strategies, including the use of direct oral anticoagulants. This article reviews current data on the optimal treatment strategy for CA-VTE in patients with OFC.</description><subject>Anticoagulants</subject><subject>Blood clots</subject><subject>Blood platelets</subject><subject>Cancer therapies</subject><subject>cancer-associated venous thromboembolism</subject><subject>Care and treatment</subject><subject>Catheters</subject><subject>Clinical medicine</subject><subject>Clinical practice guidelines</subject><subject>Complications and side effects</subject><subject>Diagnosis</subject><subject>direct oral anticoagulants</subject><subject>Head and neck cancer</subject><subject>Hemorrhage</subject><subject>Leukocytes</subject><subject>Neutrophils</subject><subject>oral and facial cancer</subject><subject>Oral cancer</subject><subject>Pancreatic cancer</subject><subject>parenteral anticoagulation</subject><subject>Patients</subject><subject>Pulmonary embolisms</subject><subject>Review</subject><subject>Risk factors</subject><subject>Thromboembolism</subject><subject>Thrombosis</subject><issn>1424-8247</issn><issn>1424-8247</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptUk1rGzEQXUpLk6a99AeUhV5KYFN9f5yCMU0TMOTi9iq00qwts7typXVK_n3lOE3iUoTQ6OnNG81jquojRheUavR1u8YCSYwwflWdYkZYowiTr1_EJ9W7nDcIcYkZfludUMkx1YSeVovr-LueYr1MYKd6Gb29v6xvk-1rO_r6yrpQwrkdHaRmlnMs9wl8_RPGuMv1cp3i0EYouw95eF-96Wyf4cPjeVb9uPq2nF83i9vvN_PZonFM66mxrSdIEwy-Bc6FFpYzyYh0GqGCgOsk0gJRCdIxpigHRVTXSuwZYxwjelbdHHR9tBuzTWGw6d5EG8wDENPK2DQF14PhnltHtQJlGUNKtFpIC1YRcI5RIYvW5UFru2sH8A7GqXR_JHr8Moa1WcU7U_6hOFekKHx5VEjx1w7yZIaQHfS9HaGYZIgqlbUQmhfq53-om7hLY_Fqz6JIcYTYM2tlSwdh7GIp7PaiZia5xkoLtjfh4j-ssjwMwcURulDwo4TzQ4JLMecE3VOTGJn9IJnnQSrkTy9teaL-nRz6BxCKv4Q</recordid><startdate>20230701</startdate><enddate>20230701</enddate><creator>Janíčková, Mária</creator><creator>Bolek, Tomáš</creator><creator>Stančiaková, Lucia</creator><creator>Nagy, Norbert</creator><creator>Mokáň, Marián</creator><creator>Samoš, Matej</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-8086-1422</orcidid><orcidid>https://orcid.org/0000-0002-5561-2560</orcidid></search><sort><creationdate>20230701</creationdate><title>How to Treat Today? Oral and Facial Cancer-Associated Venous Thromboembolism</title><author>Janíčková, Mária ; Bolek, Tomáš ; Stančiaková, Lucia ; Nagy, Norbert ; Mokáň, Marián ; Samoš, Matej</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c499t-abd20921edbe55696a547427c900be5ecf7096037e7c44835e828fb71d4445103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Anticoagulants</topic><topic>Blood clots</topic><topic>Blood platelets</topic><topic>Cancer therapies</topic><topic>cancer-associated venous thromboembolism</topic><topic>Care and treatment</topic><topic>Catheters</topic><topic>Clinical medicine</topic><topic>Clinical practice guidelines</topic><topic>Complications and side effects</topic><topic>Diagnosis</topic><topic>direct oral anticoagulants</topic><topic>Head and neck cancer</topic><topic>Hemorrhage</topic><topic>Leukocytes</topic><topic>Neutrophils</topic><topic>oral and facial cancer</topic><topic>Oral cancer</topic><topic>Pancreatic cancer</topic><topic>parenteral anticoagulation</topic><topic>Patients</topic><topic>Pulmonary embolisms</topic><topic>Review</topic><topic>Risk factors</topic><topic>Thromboembolism</topic><topic>Thrombosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Janíčková, Mária</creatorcontrib><creatorcontrib>Bolek, Tomáš</creatorcontrib><creatorcontrib>Stančiaková, Lucia</creatorcontrib><creatorcontrib>Nagy, Norbert</creatorcontrib><creatorcontrib>Mokáň, Marián</creatorcontrib><creatorcontrib>Samoš, Matej</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Pharmaceuticals (Basel, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Janíčková, Mária</au><au>Bolek, Tomáš</au><au>Stančiaková, Lucia</au><au>Nagy, Norbert</au><au>Mokáň, Marián</au><au>Samoš, Matej</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>How to Treat Today? Oral and Facial Cancer-Associated Venous Thromboembolism</atitle><jtitle>Pharmaceuticals (Basel, Switzerland)</jtitle><addtitle>Pharmaceuticals (Basel)</addtitle><date>2023-07-01</date><risdate>2023</risdate><volume>16</volume><issue>7</issue><spage>1011</spage><pages>1011-</pages><issn>1424-8247</issn><eissn>1424-8247</eissn><abstract>The exact incidence of cancer-associated venous thromboembolism (CA-VTE) in patients with oral and facial cancer (OFC) is not exactly known, and this risk is empirically considered to be low. However, this suggestion may result in disease underdiagnosis, prolong the initiation of adequate therapy, and consecutively increase CA-VTE-related morbidity and mortality. In addition, there might be specific clinical problems in the treatment of CA-VTE in patients with oral and facial cancer, such as swallowing difficulties, that might limit the possibilities of oral anticoagulation. Finally, there are limited data regarding the optimal treatment of CA-VTE in patients with oral and facial cancer, and this includes data on novel therapeutic strategies, including the use of direct oral anticoagulants. This article reviews current data on the optimal treatment strategy for CA-VTE in patients with OFC.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>37513923</pmid><doi>10.3390/ph16071011</doi><orcidid>https://orcid.org/0000-0001-8086-1422</orcidid><orcidid>https://orcid.org/0000-0002-5561-2560</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1424-8247
ispartof Pharmaceuticals (Basel, Switzerland), 2023-07, Vol.16 (7), p.1011
issn 1424-8247
1424-8247
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_5d5ac398e8a44086b967aea82ecc4367
source PubMed (Medline); Publicly Available Content Database
subjects Anticoagulants
Blood clots
Blood platelets
Cancer therapies
cancer-associated venous thromboembolism
Care and treatment
Catheters
Clinical medicine
Clinical practice guidelines
Complications and side effects
Diagnosis
direct oral anticoagulants
Head and neck cancer
Hemorrhage
Leukocytes
Neutrophils
oral and facial cancer
Oral cancer
Pancreatic cancer
parenteral anticoagulation
Patients
Pulmonary embolisms
Review
Risk factors
Thromboembolism
Thrombosis
title How to Treat Today? Oral and Facial Cancer-Associated Venous Thromboembolism
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T00%3A36%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=How%20to%20Treat%20Today?%20Oral%20and%20Facial%20Cancer-Associated%20Venous%20Thromboembolism&rft.jtitle=Pharmaceuticals%20(Basel,%20Switzerland)&rft.au=Jan%C3%AD%C4%8Dkov%C3%A1,%20M%C3%A1ria&rft.date=2023-07-01&rft.volume=16&rft.issue=7&rft.spage=1011&rft.pages=1011-&rft.issn=1424-8247&rft.eissn=1424-8247&rft_id=info:doi/10.3390/ph16071011&rft_dat=%3Cgale_doaj_%3EA759189640%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c499t-abd20921edbe55696a547427c900be5ecf7096037e7c44835e828fb71d4445103%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2843085004&rft_id=info:pmid/37513923&rft_galeid=A759189640&rfr_iscdi=true